Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide)▼ for the Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition